The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
1403014 Informal Interpretation
20140636: Eli Lilly and Company; Paul Wesjohann & Co. GmbH III
20140662: Phillips 66; Explorer Pipeline Company
20140667: Kose Corporation; Encore Consumer Capital Fund, L.P.
20140672: Providence Equity Partners VII-A L.P.; New Asurion Corporation
20140673: HGGC Fund II, L.P.; Silver Lake Partner II, L.P.
20140675: Riverside Capital Appreciation Fund VI, L.P.; Peter P. Jenkins III
20140682: Audax Private Equity Fund IV, L.P.; Levine Leichtman Capital Partners IV, L.P.
20140688: Sun Capital Partners VI, L.P.; ESCO Technologies Inc.
20140514: Memorial Health System; Passavant Memorial Area Hospital Association
20140620: Grupo Bimbo, S.A.B. De C.V.; Maple Leaf Foods Inc.
20140640: Wolters Kluwer N.V.; Third Coast Holdings, Inc.
20140643: Good Technology Corporation; Lazard Technology Partners II, LP
1403013 Informal Interpretation
20131053: CoreLogic, Inc.; TPG VI Ontario 1 AIV, L.P.
Endo Health Solutions Inc., Boca Life Science Holdings, LLC, and Boca Pharmacal, LLC, In the Matter of
Pharmaceutical companies Endo Health Sciences Inc. (Endo) and Boca Life Science Holdings, LLC and Boca Pharmacal, LLC (Boca) agreed to a settlement resolving FTC charges that Endo’s acquisition of Boca would be anticompetitive. Under the settlement, the companies will relinquish their rights to market and distribute four generic multivitamin fluoride drops for children, and will sell three other generic drugs in development.The proposed settlement preserves competition in the pharmaceutical markets for four prescription generic multivitamin drop products given to children in the United States who do not have access to fluoridated water. In addition, the FTC’s settlement preserves future competition for three generic drugs where the proposed acquisition would eliminate one likely future entrant from a very limited pool of future entrants.